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Objective: Spinal metastatic disease remains a major problem of oncological diseases.
Patients affectedmay suffer pain, spinal instability, and severe neurological deficits. Today,
palliative surgery and radiotherapy are the mainstays of therapy. In contrast, preventive
treatment strategies or treatment concepts for an early stage are lacking. Here, we have
used a syngeneic, experimental spine metastases model in the mouse to test the efficacy
of mTOR inhibition and anti-angiogenesis on the formation and progression of spinal
melanoma metastases.
Methods: We used our previously established syngeneic spinal metastases mouse
model by injecting luciferin-transfected B16 melanoma cells into the common carotid
artery. Following injection, mice were treated with everolimus, an inhibitor of the
mammalian target of rapamycin (mTOR) complex, axitinib, a tyrosine kinase inhibitor, that
blocks vascular endothelial growth factor receptors (VEGFR) 1-3, as well as placebo.
Animals were followed-up daily by neurological assessment and by repeat in vivo
bioluminescence imaging. With occurrence of neurological deficits, a spinal MRI was
performed, and mice were sacrificed. The whole spine was dissected free and analyzed
by immunohistochemical techniques.
Results: Overall survival was 23 days in the control group, significantly prolonged to
30 days (p = 0.04) in the everolimus group, and to 28 days (p = 0.04) in the axitinib
group. While 78% of mice in the placebo group developed symptomatic metastatic
epidural spinal cord compression, only 50% did so in the treatment groups. The mean
time to manifestation of paralysis was 22 days in the control group, 26 days (p = 0.10)
in the everolimus group, and 27 days (p = 0.06) in the axitinib group. Screening for
spinal metastases by bioluminescence imaging on two different time points showed
a decrease in metastatic tumor formation in the treatment groups compared to the
controls. Immunohistochemical analysis confirmed the bioactivity of the two compounds:
The Ki67 proliferation labeling index was reduced in the everolimus group and numbers
of CD31 positive endothelial cells were reduced in the axitinib group.
Conclusion: Both, the mTOR inhibitor everolimus as well as antiangiogenetic effects
by the VEGFR inhibitor axitinib showed potential to prevent and retard formation of
symptomatic spinal metastases. However, the therapeutic efficacy was only mild in this
experimental model.
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INTRODUCTION
Metastatic epidural spinal cord compression is a grave
complication for cancer patients. If untreated, a significant
spinal cord compression due to an epidural tumor mass,
most frequently originating from the vertebra, will lead to
relevant neurological deficits (1, 2). The metastatic process
involves multiple cellular steps, such as intravasation, homing,
extravasation, colony formation, and tumor growth (3). Spinal
metastases occur in approximately 10 percent of cancer patients
(4), they often represent the first manifestation of cancer (5), and
the frequency of metastatic epidural spinal cord narrowing in
cancer patients is estimated up to 8% depending on the primary
tumor (6, 7). Treatment options are surgery and radiotherapy
(8, 10). The gold standard in malignant extradural spinal cord
compression is decompressive surgery within 24 h of diagnosis
most often followed by radiotherapy (9, 10). While these
treatment concepts are palliative in nature preventive therapies
are not available and urgently needed.
In cancer treatment, targeted therapy has successfully
developed in the last decade (11). However, an optimal
pharmacological treatment specific for spinal metastatic tumors,
especially in the recurrent stage or in a prophylactic setting,
is not available yet. In our study, we chose two different
targeted therapies, with the aim to show potential effects on
spinal metastases formation and neurological outcome. Among
others, inhibitors of the enzyme mammalian target of rapamycin
(mTOR), as well as vascular endothelial growth factor receptor
(VEGFR) inhibitors, are interesting targeting pharmaceuticals.
The physiologic function of mTOR is regulating cell growth
and metabolism, that is frequently highly activated in tumor
cells (12), and the mTOR inhibitor and rapamycin derivate
everolimus has shown promising anticancer activity in various
tumor types (13, 14), with beneficial effects on bone turnover in
bone metastases patients (15). Moreover, the mTOR signaling
pathway is known to play a role in bone tissue signaling
and in bone cancer (16). Another available targeted approach
is inhibiting tumor angiogenesis, which is driven by vascular
endothelial growth factor receptors (17). The tyrosine kinase
inhibitor axitinib, currently approved for treatment of renal cell
carcinoma (18), blocks VEGFR types 1, 2, and 3, leading to
inhibition of tumor vascularization and growth (19).
In this study, we hypothesized to target the circulating tumor
cell interactions with the bone vascular network by inhibiting the
VEGFRs, and to block the mTOR signaling pathway to target
the tumor colony formation and growth. We examined, whether
targeting these signaling pathways is capable of preventing
the formation of symptomatic spinal metastases in a murine
hematogenous spinal metastases mouse model.
MATERIALS AND METHODS
Substances
Everolimus/RAD001 as well as axitinib (both Biozol, Eching,
Germany) were solved in an injection solution consisting
of 30% polyethylene glycol (PEG), 65% H2O, 5% Tween
80, and 0.1% Dimethylsulfoxid (Sigma Aldrich, Schnelldorf,
Germany). Everolimus was injected intraperitoneally (i.p.) with
a concentration of 10 mg/kg body weight, and axitinib with a
concentration of 25mg/kg body weight. Placebo was the injection
solution only. The i.p. injection volume was constantly 200µl.
Substances were stored at−20◦C and freshly thawed immediately
before use.
Firefly Luciferase Transfection, Cell Culture
and Spine Metastasis-derived Cell Line
Establishment
B16-F1 murine melanoma cells (ATCC R© CRL-6323) were
infected with a FFLUC-eGFP-Puro vector construct (B16-luc)
as described previously (20). Stable cell clone growth was
maintained in culture flasks stored at 37◦C, 5% CO2, as well
as 95% humidity. Dulbecco’s Modified Eagle Medium (DMEM)
(Invitrogen, Carlsbad, USA) was supplemented with 10% heat-
inactivated fetal calf serum (Thermo Fisher Scientific, Waltham,
USA), 50 units/ml penicillin and 50µg/ml streptomycin, as well
as 5µg/ml puromycin (SigmaAldrich, Schnelldorf, Germany) for
cell selection. The mB16-luc cell line was previously established
by in vivo selection from an already grown B16-luc spinal
tumor (20).
Approval of Animal Experiments
All animal experiments were performed according to the
UK Coordinating Committee on Cancer Research (UKCCR)
Guidelines for theWelfare of Animals in Experimental Neoplasia
(21, 22) and with the permission of the responsible local
authorities from the Charité Universitätsmedizin Berlin and the
LaGeSo Berlin.
Retrograde Carotid Artery Injection
We used female, 20 weeks old, C57/B6J mice (Jax Stock No.
000664). As previously described (20), they were anesthetized
(9mg ketamine hydrochlorid/1mg xylazine per 100 g body
weight) intraperitoneally and the area of the operation was
shaved and kept sterile during the operation. A longitude incision
of the skin was made, and under the parotid gland, the common
carotid artery was prepared and the vagus nerve was separated.
The artery was ligated permanently distal and temporarily
proximal to the aortic arch, in between incised, and a catheter
(diameter 0.8mm, filled with 0.9% sodium chloride solution)
was inserted toward the aortic arch and fixed. The temporary
ligature was opened, and a 100µl cell suspension (1× 105 mB16-
luc cells in serum-free DMEM) was slowly injected, followed by
100µl 0.9% sodium chloride, for 1min, respectively. Finally, the
common carotid artery was completely disabled, the skin was
stitched up, and mice woke up. They were randomly assigned
to the placebo and the treatment groups. Despite fully common
carotid artery occlusion, no neurological deficits, especially no
pareses of limbs, were observed (20, 23).
Treatment Schedule and Animal
Examination
All mice gained access to water and a standard laboratory diet.
Mice were treated with everolimus i.p. daily for consecutive 16
days in one group, with axitinib i.p. daily for consecutive 19 days
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in one group, as well as with placebo daily for consecutive 19 days
in one group. Drug administration started on postoperative day
1, in order to ensure the identical tumor load in all groups at
the start of therapy. Mice were examined daily, after occurrence
of neurologic deficits like limb weakness, inability to run or
paraplegia, or a bad health status, a spinal MRI was performed
and mice were immediately sacrificed. The spine and brain were
dissected, and frozen for further histological analysis.
Bioluminescence Imaging
Imaging was performed on postoperative days 11 and 22 on
every mouse with the IVIS Lumina II equipment (Caliper LS,
Waltham, USA). During the procedure, mice were anesthetized
with 2% isoflurane (Forene, Wiesbaden, Germany), and they
were shaved along the spine for better imaging. D-luciferine
(Caliper LS, Waltham, USA) was administered i.p. analogous to
the manufacturer’s protocol (30 mg/ml, 10 µl/g body weight)
in order to activate cleavage by luciferase, selectively expressed
by the tumor cells. After 5min, mice were transferred into the
imaging system. After an exposure time of 5min, signals were
measured as relative light units with Living Image 3.1 software
(Perkin Elmer, Waltham, USA). A demarcated area above the
spine was defined as one hot spot if it showed a clear signaling and
could be distinguished from other neighboring signaling areas.
Magnetic Resonance Imaging
MRI studies were performed at a seven Tesla small-animal
system BioSpec 70/20 (Bruker BioSpin MRI GmbH, Ettlingen,
Germany) with a BGA-12S HP gradient system and Bruker
software Paravision 6.0.1. For imaging, a 1H−86mm quadrature
volume resonator and a receive—only 1H—phased array rat
brain surface coil were used. DuringMRI examination, mice were
placed on a heated circulating water blanket to ensure constant
body temperature of 37◦C. Anesthesia was maintained with 2.5–
1.5% isoflurane delivered in an O2/N2O mixture (0.3/0.7 l/min)
via a facemask under constant ventilation monitoring (Small
Animal Monitoring & Gating System, SA Instruments, New
York, USA). T2-weighted images of the whole mouse spine in
the sagittal plane were made. For image acquiring, Paravision
6.0.1 software (Bruker, Billerica, USA) was used. For metastases
number analysis, vertebral body as well as intraspinal tumors and
tumors of the posterior column were counted.
Spine Fixation and Preparation
For fixation, a whole animal perfusion was necessary. Mice
were deeply anesthetized with 9mg ketamine hydrochlorid/1mg
xylazine per 100 g body weight i.p. A thoracotomy was
performed, a needle was placed into the left ventricle,
and the right atrium was opened for outflow. Perfusion
began with sodium chloride, until a bright liver indicated
a good effect, and was completed by infusion with 4%
paraformaldehyde (24). Whole spines were dissected, muscle
tissue was completely removed, and samples were fixed
in 4% paraformaldehyde solution on ice for 4 h. Then,
spines were decalcified with 0.5M EDTA solution at 4◦C
for 24 h. After that, samples were stored in 20% sucrose
and 2% polyvinylpyrrolidone for 24 h at 4◦C. Finally,
spines were embedded in a solution of 8 g gelatin, 2 g
polyvinylpyrrolidone, and 20 g sucrose in 100ml PBS, and
stored at−80◦C (25).
Immunohistochemistry
Spine samples were transferred to a cryostat (Leica, Wetzlar,
Germany), and cryosections were made at −20◦C. Slides were
dried and stored at −20 ◦C. For immunostaining, they were
thawed and fixed in methanol (−20◦C for 5min) followed by
30min incubation with blocking buffer (1% casein in PBS).
The primary antibodies against Ki67 (Thermo Fisher Scientific,
Waltham, USA) and CD31/PECAM-1 (BD Pharmingen,
Franklin Lakes, USA) as well as FITC-conjugated and Cy3-
conjugated secondary antibodies (Dianova, Hamburg, Germany)
were added for 2 h, respectively. Cell nuclei staining was
performed by incubation with 4’,6-diamidino-2-phenylindole
(1:100 in PBS, Roth, Karlsruhe, Germany) for 5min. Slides
were covered with Immu-Mount (Thermo Fisher Scientific,
Waltham, USA). By fluorescence microscopy, 30 high-power
fields from three different spinal metastases per group were
randomly chosen, Ki67 positive and negative stained cell
nuclei were compared by percentage with ImageJ software
(NIH, Bethesda, USA), CD31 positive endothelial cells
were counted and subsequently analyzed. Negative controls
without processing primary antibodies did not display any
specific immunoreactivity.
Statistical Analysis
Data were shown as mean ± standard deviation. The Mantel-
Cox test (logrank test) was used for survival analysis as
well as analysis for neurological deficit occurrence. For
immunohistochemical analysis, the Kruskal–Wallis test was used
to test for significant differences among groups (p = 0.009
for the Ki67 analysis, p < 0.001 for the CD31 analysis), and
the Mann–Whitney U-test was applied for group comparisons.
Differences with p < 0.05 were considered as statistically
significant. Statistical differences were calculated with SPSS
software (IBM, Armonk, USA) as well as with GraphPadPrism
software (La Jolla, USA).
RESULTS
Spinal Epidural Metastases Development
In our mouse model, bony metastases in the spine with
epidural spinal cord compression developed within 2–3 weeks,
as previously shown (20, 26), without solid brain metastases
formation, at least in the corresponding time periods, which
could also lead to neurological deficits. Spine column explants
already macroscopically showed black melanoma metastases
(Figure 1A). Both bioluminescence imaging (Figure 1B) and
spinal MRI (Figure 1C) allowed to assess spinal metastatic
burden in vivo. Conventional histology illustrated epidural
metastatic spinal cord compression and demonstrated tumors
that infiltrated the trabecular vertebral bone structure and
compressed the dura and spinal cord (Figures 1D,E).
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FIGURE 1 | (A) A spine column explant with a black melanoma metastasis. (B) Correlating to bioluminescence signals, a (C) spinal sagittal plane MRI shows a
vertebral body metastasis, blue arrow, as well as a metastasis with epidural spinal cord compression, red arrow. (D) Tumor cells infiltrated the trabecular bony
structure (representative hematoxylin and eosin staining). (E) Intraspinal epidural tumor (+), dura impression (*), nervous tissue (#). Bars indicate 100µm.
Prolonged Overall Survival
Treatment with everolimus or axitinib prolonged overall survival
of tumor bearing mice by up to 30% when compared to placebo
(Figure 2A). In the control group, mean survival was 23± 4 days
compared to 30± 8 days in the everolimus group and 28± 6 days
in the axitinib group (Figure 2C). The differences compared to
the placebo group were statistically significant (p= 0.04).
Effect on Neurological Deficit
In contrast to survival, the effect on formation of spine metastasis
was less pronounced. Seventy-eight percent of mice in the control
group showed paralysis of upper or lower limbs, compared to
50% in the treatment groups (Figures 2B,C). MRI confirmed
that all of these episodes of neurological deterioration were
related to a spinal metastasis. The time to development of these
neurological deficits was, however, not statistically different.
Mean time to neurological deficit was 22 ± 5 days in the control
group. In the everolimus group, time to paresis was 26 ± 2 days
(p = 0.10) and in the axitinib group, time to neurological deficit
was 27± 6 days (p= 0.06; Figure 2C).
Spinal MRI Directly After Onset of
Neurological Deficits
After onset of a neurological deficit, a whole spinal MRI was
performed and thereafter, mice were sacrificed. The numbers of
spinal metastases were counted on the spinal MRI in sagittal cuts.
We found a mean metastases number of 2 ± 1 in the control
group, 2 ± 3 in the everolimus group, and 2± 1 in the axitinib
group, respectively (p= 0.91; Figure 2C).
Bioluminescence Tumor Visualization
We conducted a bioluminescence spine metastatic tumor
screening after postoperative days 11 and 22 (Figure 3). Areas of
spinal hot spots correlated well with the results of MR imaging
(Figures 1B,C). After 11 days, we observed similar numbers
of metastases per mouse in the experimental group (control,
everolimus and axitinib group 1 ± 1, 2 ± 1, 1 ± 1, respectively;
p > 0.05), as well as similar numbers on postoperative day 22 (2
± 2, 2 ± 1, 2 ± 1, respectively; p > 0.05). A heightened signal
intensity over time of already existing metastases, indicating
tumor growth, could be measured in all mice.
Histological Analysis
Next we aimed at understanding the mild effects in the treatment
arms. To reveal a possible treatment effect on metastases
proliferation, we examined spinal tumor tissue by Ki67 staining.
In the control group, there was a mean of 22 ± 6% of stained
cell nuclei, compared to 18 ± 5% in the everolimus group (p =
0.013), and 22 ± 5% in the axitinib group (Figures 4A–D). To
assess anti-angiogenic activities, we stained for the endothelial
cell marker CD31. There was a mean number of endothelial
cells per high-power field of 25 ± 4 cells in the controls, of
25 ± 5 cells in the everolimus group, and of 19 ± 5 cells in
the axitinib group. The difference between the axitinib group
and the control group was statistically significant (p < 0.001).
Furthermore, we observed larger vessels within spinal metastases
of axitinib treated mice (Figures 4E–H).
DISCUSSION
In the present study we have shown that in our mouse
model bony metastases developed within the spine causing
epidural spinal cord compression, and it is possible to
monitor the occurrence and numbers of spinal metastases by
bioluminescence imaging or MRI. The principal novel findings
are a significant prolonged overall survival of mice treated
with the mTor inhibitor everolimus or after therapy with
the VEGFR blocker axitinib, as well as a prolonged time to
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FIGURE 2 | Overall survival, time to neurological deficits as well as clinical symptoms. (A) Kaplan-Meier survival plots, comparing the control group (black), everolimus
group (green), and axitinib group (red) with a significantly (*p = 0.04) lower mortality in the treatment groups. (B) Time to neurological deficit, defined by extremity
paresis, with a tendency to a prolonged time to this event during everolimus or axitinib treatment, but without reaching statistical significance (everolimus group p =
0.10, axitinib group p = 0.06). (C) This table summarizes data of all experimental groups. The day number describes the postoperative day, when the respective event
leading to death occurred.
neurological deficit, triggered by a spinal metastatic tumor, in
both treatment modalities.
Malignant spinal cord compression caused by spinal
metastases can lead to neurological symptoms up to paraplegia
with a serious reduction in quality of life. Generally, tumor
metastases are located most frequently in the lungs and liver, but
then followed by the skeletal system including the spine (27).
Malignant spinal cord compression can indicate an advanced
tumor stage, verified by the observation of a limited overall
survival after diagnosis (2, 28).
In the acute situation of a neurological deficit, surgery
is the therapy of choice, in order to improve or retain
neurologic function. If a patient is not operable, radiotherapy
combined with corticosteroids can be initiated (9). Most
often, a resection is accompanied by local radiotherapy and,
depending on the tumor stage, systemic chemotherapy (2).
Nevertheless, the local recurrence rate after treated symptomatic
spinal metastases is about 7 to 14 percent (2, 29, 30). To
focus on these patients, targeted therapies as an adjunct to
the standard treatment seem to be promising, with the aim
to prevent as well as treat these tumors, and to stop the
growth of other possibly existing metastatic tumors within
the spine.
Therefore, we previously established a hematogenous spinal
metastases mouse model to examine basic principles of spinal
metastases formation (20). We adapted a bone metastases mouse
model (31) by injecting tumor cells into the common carotid
artery to avoid the pulmonary filter system, so that tumor
cells spread into the arterial blood leading to an endogenously
spinal metastases formation process. It is assumed that tumor
cells are reaching the vertebral bodies by a hematogenous route
(32), and arterial embolization seems to be the most relevant
mechanism of metastasis development (33). The distribution
of spinal metastases is about 60% in the thoracic, 25% in the
lumbar, and 15% in the cervical spine (1, 6, 34), with similar
distributions in our spinal model shown by bioluminescence
monitoring, indicating a matchable system regarding to the
mechanism of spinal metastases formation, which is, however,
still not fully understood.
In our model, we used murine melanoma cells (35), obtaining
the advantage to use immunocompetent mice, and to retain
potential influences of the immune system. For cell injections,
we used our stable cell line mB16, established from solid grown
B16 spinal metastases in this model by in vivo selection, with
a significantly higher potential to metastasize to the spine (20).
The advantage is that mice, after tumor cell injections, generally
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FIGURE 3 | Metastases visualization by in vivo luminescence imaging. Left side shows mice on postoperative day 11, right side day 22. Blue color implies low signal
intensity, red color high signal intensity, as relative light units in the color scale. In the placebo group, 5 mice already died before measurement on postoperative day 22
could be performed, in the treatment groups, all mice could be measured. A heightened signal intensity over time of metastases correlating with tumor growth could
be shown in all mice.
did not suffer from significant tumor burden in other organs like
the lung, liver or brain, and a nearly spine-specific tumor model
was available.
One aim of our study was to confirm this preclinical model
as valid for therapeutic studies regarding spinal metastases
formation. Moreover, we applied two different targeted therapy
approaches with the following hypothetical impacts: On the one
hand, we wanted to target the potential circulating melanoma
cell interactions with the bone vascular network by inhibiting the
VEGFRs, in order to target the vascular formation step in the
metastases origination cascade. On the other hand, we blocked
the mTOR signaling pathway to potentially target tumor bone
colony formations and spine metastasis growth, as the last step
in metastasis bone formation.
We could find a significantly prolonged overall survival in
both therapy groups. Placebo treated mice lived 23 days on
average, after everolimus or axitinib therapy, mice survived 7
(prolonged by 30%) and 5 days (prolonged by 25%) longer,
respectively. This indicates a general antitumor effect in the
systemic compartment. In order to assess symptomatic spinal
metastases, we focused on acute neurological deficits, e.g., limb
paresis. A causal spinal cord compression was verified by MRI.
Here, we found a 18% prolonged time after mTOR inhibition
by everolimus, and a 23% prolongation after VEGFR blockade
via axitinib therapy, until neurological deficits due to spinal cord
compression occurred. We state that our model serves as a valid
system for examining therapy responses on spinal metastases
formation, and for evaluation of the neurological outcome.
The luminescence reporter imaging for tumor visualization
served to detect possible dynamic effects on spinal metastases
formation and growth in vivo (36). Between two different time
points during therapy, on postoperative days 11 and 22, we did
not detect any significant change in the numbers of spinal tumor
hot-spots among groups. In the spinal MRI, we detected similar
numbers of metastases in comparison with the bioluminescence
method on postoperative day 22, considering the different time
points the methods were applied. The bioluminescence screening
was used on two defined time points, whereas the spinal MRI
was performed directly after the occurrence of a neurological
deficit in order to show the responsible spinal tumor, which
apparently began on different dates for each mouse. Though,
we presume a higher increase in numbers of novel developing
spinal tumor hot-spots during axitinib therapy, in contrast to
a continuous growth of already early existing metastases in the
everolimus group. More frequent time intervals could reveal
clearer effects, and being aware of the limited validity, i.a. the
small differences and the small number of mice in the placebo
group on the second time point, it seems possible that VEGFR
inhibition could delay the time point of the development of
solid spinal metastases, similar to a prophylaxis, maybe due to
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FIGURE 4 | Immunohistochemical analysis. Graphs show the summary of data from all randomly chosen high-power fields from 3 different spinal metastases per
group. (A–D) Fluorescence-provided Ki67 stainings of tumor cell nuclei in the placebo group, axitinib group and everolimus group. The fraction of proliferating cells
was lowered in the everolimus group (p = 0.013). (E–H) Numbers of endothelial cells marked by CD31 immunostainings revealing a lowered number of endothelial
cells as well as larger tumor vessels in axitinib treated mice (p < 0.001).
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angiogenesis inhibition after tumor cells are entrapped passively
(26). For example, in prostate tumors, the expression levels of
VEGF and VEGFRs were higher at the bone metastases site
compared to the primary tumors, indicating the importance of
angiogenesis in metastasis development to the bone (37), and
vascular factors could encourage the nesting of tumor cells in
the bone (38). Angiogenesis inhibition could be revoked by
tumor cell adaptation processes, and the antiangiogenic effects
could be pronounced in early stages of metastases formation.
At this time point, tumors could be most accessible to targeted
VEGFR inhibition, with the focus on vessel formation, delaying
the process of building their own blood supply. This theory could
be addressed in future projects.
Further immunohistochemical analysis showed that in late
stage spinal metastases, the proliferation of tumor cells was
slightly lowered after mTOR inhibition, detected by a decrease in
the Ki67 labeling index. VEGFR inhibition did not influence the
tumor proliferation rate, but reduced the number of endothelial
cells, and larger vessels were observed, indicating a normalization
of the tumor vasculature, and possible antiangiogenic effects.
This indicated two different impacts on malignant tumor
properties after two different targeted treatments against spinal
metastases, also confirming the bioactivity of the two applied
compounds. Here, the mild histological effects could not finally
confirm the expected mode of actions as a therapy target, and our
applied therapy did not elicit a significant impact on the spinal
tumor compartment, though proved significant prolongation of
the overall survival as well as prolongation of the occurrence of
neurological deficits.
In this study, we demonstrated a feasible preclinical
mouse model suitable for investigating targeted therapy
approaches against metastatic spinal cord compression. It is
important to better understand the molecular mechanisms in
spinal metastases formation and further experimental data is
necessary, with the general aim to offer patients individualized
therapy options.
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